144 related articles for article (PubMed ID: 19820369)
1. Prognostic impact of parity in 493 uterine sarcoma patients.
Albrektsen G; Heuch I; Wik E; Salvesen HB
Int J Gynecol Cancer; 2009 Aug; 19(6):1062-7. PubMed ID: 19820369
[TBL] [Abstract][Full Text] [Related]
2. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases.
Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Cosio S; Tisi G; Lissoni A; Ferrero AM; Cristofani R
Eur J Gynaecol Oncol; 2002; 23(4):295-9. PubMed ID: 12214727
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and surgical therapy of uterine sarcoma.
Vrzic-Petronijevic S; Likic-Ladjevic I; Petronijevic M; Argirovic R; Ladjevic N
Acta Chir Iugosl; 2006; 53(3):67-72. PubMed ID: 17338203
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Gynecol Oncol; 2008 Oct; 111(1):74-81. PubMed ID: 18657852
[TBL] [Abstract][Full Text] [Related]
5. Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran.
Ghaemmaghami F; Karimi-Zarchi M; Gilani MM; Mousavi A; Behtash N; Ghasemi M
Asian Pac J Cancer Prev; 2008; 9(3):421-6. PubMed ID: 18990014
[TBL] [Abstract][Full Text] [Related]
6. Parity and time interval since childbirth influence survival in endometrial cancer patients.
Albrektsen G; Heuch I; Wik E; Salvesen HB
Int J Gynecol Cancer; 2009 May; 19(4):665-9. PubMed ID: 19509568
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors associated with uterine sarcomas: the experience of a single institution.
Barquet-Muñoz SA; Isla-Ortiz D; Montalvo-Esquivel G; Cantú-de-León D; Salcedo-Hernández RA; Cordoba-Gonzalez V; Herrera-Gómez Á
J Obstet Gynaecol; 2019 Feb; 39(2):231-236. PubMed ID: 30354797
[TBL] [Abstract][Full Text] [Related]
8. Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database.
Hosh M; Antar S; Nazzal A; Warda M; Gibreel A; Refky B
Int J Gynecol Cancer; 2016 Jul; 26(6):1098-104. PubMed ID: 27177280
[TBL] [Abstract][Full Text] [Related]
9. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality.
Nordal RR; Thoresen SO
Eur J Cancer; 1997 May; 33(6):907-11. PubMed ID: 9291814
[TBL] [Abstract][Full Text] [Related]
10. Poorer survival of nulliparous women with endometrial carcinoma.
Salvesen HB; Akslen LA; Albrektsen G; Iversen OE
Cancer; 1998 Apr; 82(7):1328-33. PubMed ID: 9529025
[TBL] [Abstract][Full Text] [Related]
11. The role of adjuvant radiation in uterine sarcomas.
Sampath S; Schultheiss TE; Ryu JK; Wong JY
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):728-34. PubMed ID: 19700247
[TBL] [Abstract][Full Text] [Related]
12. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.
Abeler VM; Røyne O; Thoresen S; Danielsen HE; Nesland JM; Kristensen GB
Histopathology; 2009 Feb; 54(3):355-64. PubMed ID: 19236512
[TBL] [Abstract][Full Text] [Related]
13. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan.
Sagae S; Yamashita K; Ishioka S; Nishioka Y; Terasawa K; Mori M; Yamashiro K; Kanemoto T; Kudo R
Oncology; 2004; 67(1):33-9. PubMed ID: 15459493
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathologic characteristics and prognosis factors of uterine sarcomas in central Tunisia].
Khlifi A; Fathallah K; Zbidi C; Hidar S; Bibi M; Khairi H
Bull Cancer; 2014; 101(7-8):669-80. PubMed ID: 25091649
[TBL] [Abstract][Full Text] [Related]
15. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
16. Association of time since last birth, age at first birth and parity with breast cancer survival among parous women: a register-based study from Norway.
Alsaker MD; Opdahl S; Romundstad PR; Vatten LJ
Int J Cancer; 2013 Jan; 132(1):174-81. PubMed ID: 22511284
[TBL] [Abstract][Full Text] [Related]
17. Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri.
Vongtama V; Karlen JR; Piver SM; Tsukada Y; Moore RH
AJR Am J Roentgenol; 1976 Jan; 126(1):139-47. PubMed ID: 175673
[TBL] [Abstract][Full Text] [Related]
18. Uterine sarcoma-current management and experience from a regional cancer centre in North India.
Biswas A; Patel F; Kumar P; Srinivasan R; Bera A; Sharma SC; Rajwanshi A
Arch Gynecol Obstet; 2013 Oct; 288(4):873-82. PubMed ID: 23580012
[TBL] [Abstract][Full Text] [Related]
19. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
[TBL] [Abstract][Full Text] [Related]
20. Uterine sarcoma in Israel: a study of 104 cases.
Schwartz Z; Dgani R; Lancet M; Kessler I
Gynecol Oncol; 1985 Mar; 20(3):354-63. PubMed ID: 2982707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
